Status:
UNKNOWN
Bronchoscopic Score for Prediction of Herpes Simplex-virus Type 1 (HSV-1) Reactivation
Lead Sponsor:
University Hospital Muenster
Conditions:
Tracheobronchitis
Herpes Simplex Infection
Eligibility:
All Genders
18+ years
Brief Summary
Tracheobronchial reactivation of HSV-1 is a common finding in critically ill patients and is associated with longer intensive care unit (ICU) stay and mechanical ventilation. At present it is unclear ...
Detailed Description
Critically ill adult patients having a first diagnostic or therapeutic bronchoscopy are included. A standardized bronchoscopic score (values from 0 to 6) is assessed by an experienced ICU physician. ...
Eligibility Criteria
Inclusion
- 1\. Adult patients (age ≥18 years) 2. Indication for bronchoscopy during intensive care unit stay 3. Written informed consent
Exclusion
- 1\. Solid organ transplantation 2. Present coronavirus disease 2019 (COVID-19) infection 3. Previous bronchoscopy during present hospital stay 4. Pregnancy 5. Known primary or secondary severe immunodeficiency
Key Trial Info
Start Date :
September 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05331417
Start Date
September 30 2021
End Date
August 1 2025
Last Update
April 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Münster
Münster, Germany, 48149